Wedbush Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price

Key Points

• Wedbush raised its price target on Tango Therapeutics from $15 to $19 and kept an "outperform" rating, implying about a 13% upside, while the consensus analyst target is $18.25 with nine Buy, one Hold and one Sell rating (average: Moderate Buy).
• Insiders have been selling recently (113,633 shares worth ~$1.42M in the last 90 days), but large institutional investors—including Adage and Goldman Sachs—significantly increased positions, leaving roughly 79% of the stock owned by institutions.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) had its price target boosted by stock analysts at Wedbush from $15.00 to $19.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Wedbush's price target suggests a potential upside of 13.10% from the company's previous close.

TNGX has been the subject of several other research reports. B. Riley Financial upped their price objective on shares of Tango Therapeutics from $8.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, November 18th. Guggenheim upped their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Friday. Weiss Ratings reiterated a "sell (e+)" rating on shares of Tango Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus started coverage on Tango Therapeutics in a report on Wednesday, December 3rd. They set a "buy" rating and a $15.00 target price on the stock. Finally, HC Wainwright upped their target price on Tango Therapeutics from $13.00 to $27.00 and gave the stock a "buy" rating in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $18.25.

Tango Therapeutics Stock Performance

Shares of TNGX stock opened at $16.80 on Friday. Tango Therapeutics has a 1 year low of $1.03 and a 1 year high of $16.97. The firm has a market capitalization of $2.26 billion, a PE ratio of -18.06 and a beta of 1.76. The stock has a fifty day moving average of $11.70 and a two-hundred day moving average of $9.37.

Insider Buying and Selling

In other Tango Therapeutics news, CFO Daniella Beckman sold 10,317 shares of the company's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $126,486.42. Following the transaction, the chief financial officer owned 184,297 shares of the company's stock, valued at approximately $2,259,481.22. This represents a 5.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barbara Weber sold 30,519 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $374,162.94. Following the sale, the director owned 1,629,254 shares of the company's stock, valued at $19,974,654.04. This trade represents a 1.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 113,633 shares of company stock worth $1,420,857 in the last ninety days. 7.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. boosted its position in shares of Tango Therapeutics by 322.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company's stock valued at $93,986,000 after purchasing an additional 8,096,924 shares during the period. Caligan Partners LP purchased a new stake in Tango Therapeutics during the fourth quarter valued at about $33,047,000. Goldman Sachs Group Inc. boosted its holdings in shares of Tango Therapeutics by 227.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,942,414 shares of the company's stock worth $43,790,000 after buying an additional 3,432,939 shares during the period. Logos Global Management LP increased its position in shares of Tango Therapeutics by 342.1% in the fourth quarter. Logos Global Management LP now owns 4,200,000 shares of the company's stock worth $37,212,000 after acquiring an additional 3,250,000 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new stake in shares of Tango Therapeutics during the third quarter valued at approximately $25,924,000. 78.99% of the stock is owned by institutional investors and hedge funds.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.